AHIMA names Sheridan as president

Justine Varieur Cadet | | Health Exec | Informatics
Patty Thierry Sheridan, MBA, has been elected president of the American Health Information Management Association (AHIMA).

Sheridan will serve a three-year term, consisting of president-elect in 2011, president in 2012 and past-president in 2013. 

Sheridan is currently president of Care Communications, a health information management consulting and staffing firm. She served Care Communications in several capacities, including as vice president of operations and chief information officer before becoming president in 2004. Sheridan’s past tenure at the AHIMA includes a volunteer term on the organization’s board of directors (2007-2009) and past experience serving as chief operating officer in 1993, acting executive director in 1994 and vice president of professional development from 1995 to 1998.

Justine Varieur Cadet

Related Content

Alabama security breach exposes personal information of cardiologists, heart patients
AI helps cardiologists deliver personalized healthcare—but there is still plenty of work to do
Best in KLAS 2024: New rankings for cardiovascular information systems, hemodynamic solutions
Best in KLAS 2024 rankings released, showcasing medical imaging IT systems
Cloud image storage for radiology is a growing trend in healthcare
Indiana hospitals reduce nuisance alerts by 77% with medication decision support software

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.